Target intelligence / Profile preview

ALMS1 centrosome and basal body associated protein (ALMS1)

Target
ALMS1
Molecular classification
Other (Centrosome- and basal body-associated protein; Ciliopathy protein), Associated with ciliary function and centrosome organization
01

Overview

ALMS1 centrosome and basal body associated protein (ALMS1) is a large (~0.5 megadalton) protein that localizes predominantly to the base of centrioles and the basal body of primary cilia. Its precise cellular functions are not fully characterized, but ALMS1 is implicated in the maintenance and function of cilia, centrosome cohesion, actin cytoskeleton organization, intracellular trafficking (including GLUT4 recycling), and possibly transcriptional regulation. Mutations in ALMS1 are responsible for Alström syndrome, a rare autosomal recessive childhood-onset disorder characterized by progressive multi-organ dysfunction, including retinal degeneration, sensorineural hearing loss, obesity, type 2 diabetes, cardiomyopathy, renal and hepatic disease, and fibrosis. ALMS1 defects are considered ciliopathies, linking the protein to other disorders of ciliary dysfunction. Although some evidence points to roles in cell cycle regulation and vascular/renal physiology, there are no approved drugs that directly target ALMS1. Diagnosis typically relies on genetic analysis of ALMS1 mutations and clinical syndrome recognition[2][3][5][6][7].

Other names
Alstrom syndrome protein 1Centrosome-associated protein ALMS1KIAA0328ALSSAlstrom syndrome 1
02

Mechanism of action

None known (No drugs or small molecules act directly upon ALMS1; mechanistic studies are ongoing.)

03

Biological functions

Maintenance and organization of primary ciliaEndosomal (intracellular) traffickingActin organization and cytoskeletal regulationCentrosome cohesionTranscriptional regulation (possible)Cell cycle regulationMicrotubule organizationGlucose transporter 4 (GLUT4) recyclingRegulation of blood pressure and kidney sodium handling
04

Disease associations

Alström syndrome (primary disease; multisystem ciliopathy)Diabetes and insulin resistance (due to pancreatic effects)Obesity (due to hypothalamic and metabolic defects)Retinal degeneration (due to ciliary dysfunction)Sensorineural hearing lossDilated cardiomyopathyFibrosis (multi-organ)Hypertension and chronic kidney disease
05

Safety considerations

Therapeutic targeting of ALMS1 is not established; safety concerns relate to the consequences of gene/protein deficiency.Major clinical challenge: multisystem progressive disease, difficulty with phenotypic heterogeneity and organ fibrosis.No known concerns for direct pharmacologic targeting, as no drugs target ALMS1.
06

Interacting drugs

None known (No approved drugs directly target ALMS1[3][5][7]. Disease is managed symptomatically.)
07

Biomarkers

Mutations in ALMS1 gene (used for diagnosis of Alström syndrome)Clinical features: combination of retinal dystrophy, obesity, diabetes, sensorineural hearing loss, cardiomyopathy, and multi-organ dysfunctionNo pharmacodynamic/therapeutic biomarkers used for ALMS1 as a target.

Beyond the preview

Go deeper on ALMS1 centrosome and basal body associated protein (ALMS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALMS1 centrosome and basal body associated protein (ALMS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call